STAT+: Biotech startup raises $175 million to advance Alzheimer’s antibody therapy

STAT News · Feb 18, 2026 · Collected from RSS

Full Article

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud. You can reach Allison on Signal at AllisonDeAngelis.01.With two approved Alzheimer’s antibody therapies already on the market, is there room for more such treatments designed to clear out the sticky amyloid plaques associated with the disease? Well, investors at Fairmount, Venrock, Wellington Management, and TCGX believe so. They and other firms have handed $175 million over to a new company, Korsana Biosciences, to develop an Alzheimer’s medicine. Korsana launched Wednesday with plans to test a new treatment for Alzheimer’s called KRSA-028. Like generations of potential treatments before it, KRSA-028 is designed to break down a protein called amyloid that clumps up in the brains of Alzheimer’s patients. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe